Synlogic Inc (SYBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synlogic Inc (SYBX) has a cash flow conversion efficiency ratio of -0.139x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.44 Million) by net assets ($10.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Synlogic Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Synlogic Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SYBX liabilities breakdown for a breakdown of total debt and financial obligations.
Synlogic Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synlogic Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Evolva Holding SA
SW:EVE
|
-0.071x |
|
Mountain Lake Acquisition Corp. Right
NASDAQ:MLACR
|
N/A |
|
Sentra Food Indonesia Tbk PT
JK:FOOD
|
-0.117x |
|
Tri-Mode System M Bhd
KLSE:0199
|
0.023x |
|
Vape Holdings Inc
NASDAQ:VAPE
|
-0.091x |
|
Lendway Inc.
NASDAQ:LDWY
|
-0.168x |
|
Atlas Cycles (Haryana) Limited
NSE:ATLASCYCLE
|
0.001x |
|
Sersol Bhd
KLSE:0055
|
0.010x |
Annual Cash Flow Conversion Efficiency for Synlogic Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Synlogic Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Synlogic Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.75 Million | $-31.66 Million | -2.483x | -105.18% |
| 2023-12-31 | $42.66 Million | $-51.61 Million | -1.210x | -75.72% |
| 2022-12-31 | $82.61 Million | $-56.89 Million | -0.689x | -94.28% |
| 2021-12-31 | $147.27 Million | $-52.20 Million | -0.354x | -3.18% |
| 2020-12-31 | $115.14 Million | $-39.55 Million | -0.344x | +28.58% |
| 2019-12-31 | $156.91 Million | $-75.47 Million | -0.481x | -40.54% |
| 2018-12-31 | $124.10 Million | $-42.47 Million | -0.342x | +6.29% |
| 2017-12-31 | $85.04 Million | $-31.05 Million | -0.365x | +11.15% |
| 2016-12-31 | $60.35 Million | $-24.80 Million | -0.411x | -65.33% |
| 2015-12-31 | $85.02 Million | $-21.14 Million | -0.249x | -185.33% |
| 2014-12-31 | $-47.95 Million | $-13.97 Million | 0.291x | +34.16% |
| 2013-12-31 | $-29.91 Million | $-6.50 Million | 0.217x | -- |
About Synlogic Inc
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-system… Read more